References
1)World Health Organization HO (2020) Coronavirus disease 2019
(COVID-19) situation report Available
fromhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
2)Lin L, Lu L, et al. (2020) Hypothesis for potential pathogenesis of
Sars-CoV-2 infection a review of immune changes in patients with viral
pneumonia. Emerg Microbes Infect.
3)Zou Q, Zheng S et al. Influenza A-associated severe pneumonia in
hospitalized patients: risk factors and NAI treatments. Int J Infect Dis
2020.
4)Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020.
5)Stefan R Bornstein et al. Practical recommendations for the management
of diabetes in patients with COVID-19 Lancet Diabetes Endocrinol 2020.
6)Hoffmann M, Kleine-Weber H et al. SARS-CoV-2 cell entry depends on
ACE2 and TMPRSS2 and is blocked by a clinically proven protease
inhibitor. Cell 2020.
7)Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological
evidence for a role in diabetes. Mol Cell Endocrinol 2009.
8)Yang JK, Lin SS et al. Binding of SARS coronavirus to its receptor
damages islets and causes acute diabetes. Acta Diabetol 2010.
9)Raj VS, Mou H et al. Dipeptidyl peptidase 4 is a functional receptor
for the emerging human coronavirus-EMC. Nature 2013.
10)Li K, Wohlford-Lenane CL, Channappanavar R et al. Mouse-adapted MERS
coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc
Natl Acad Sci USA 2017.
11)Fan C, Wu X et al. A Human DPP4- Knockin Mouse’s Susceptibility to
Infection by Authentic and Pseudotyped MERS-CoV. Viruses 2018.
12)Yang W, Cai X et al. DPP-4 inhibitors and risk of infections: a
meta-analysis of randomized controlled trials.
Diabetes Metab Res Rev 2016.
13)Raj VS, Mou H et al. Dipeptidyl peptidase 4 is a functional receptor
for the emerging human coronavirus-EMC. Nature (2013)
14)Iacobellis G. COVID-19 and diabetes: can DPP4 inhibition play a
role? DiabetesResClinPract (2020).